Tag: inactivated vaccines market trends

  • Inactivated Vaccines Market CAGR Forecast Through 2030: Key Trends Shaping Industry Expansion

    Inactivated Vaccines Market CAGR Forecast Through 2030: Key Trends Shaping Industry Expansion

    Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.

    Inactivated Vaccines Market Poised To Hit $8.06 Billion By 2030 With A 5.1% CAGR

    The inactivated vaccines market size has experienced steady expansion in recent years. Its valuation is anticipated to rise from $6.37 billion in 2025 to $6.61 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 3.9%. The market’s historic growth can be ascribed to factors like an increasing prevalence of infectious diseases, developments in virology research, government funding for immunization efforts, the expansion of healthcare infrastructure, and public awareness campaigns promoting vaccination.

    The inactivated vaccines market is projected to experience substantial expansion in the coming years. Its valuation is anticipated to reach $8.07 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 5.1%. This growth trajectory throughout the forecast period stems from factors such as an expanding elderly demographic, improved healthcare accessibility in developing economies, innovations in vaccine delivery mechanisms, a surge in worldwide immunization efforts, and the increasing uptake of multi-dose and combination vaccines. Key developments expected during this timeframe encompass improvements in vaccine creation methods, an expansion of cold chain logistical networks, a rising need for childhood vaccines, the proliferation of governmental immunization schemes, and the ongoing creation of combined vaccines.

    Get A Free Sample Report With In-Depth Market Insights:

    https://thebusinessresearchcompany.com/sample_request?id=98098142&type=smp&name=Inactivated%20Vaccines%20Market%20Report%202026&utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

    Inactivated Vaccines Market Development Factors: What’s Supporting Demand?

    The rising occurrence of infectious diseases is projected to drive the expansion of the inactivated vaccine market going forward. Infectious diseases are conditions caused by agents such as bacteria, viruses, fungi, or parasites that can spread between people, leading to various symptoms and health complications, with tuberculosis being one example. Inactivated vaccines employ non-living pathogens to induce an immune response, thereby preventing diseases like polio, hepatitis A, and influenza. For example, in November 2023, the Centers for Disease Control and Prevention, a national public health agency based in the USA, reported that the number of tuberculosis patients in the USA increased from 8,320 in 2022 to 9,615 in 2023, indicating an increase of 1,295 cases. Hence, the increasing prevalence of infectious diseases is fueling the growth of the inactivated vaccine market.

    Inactivated Vaccines Market Segment Performance And Emerging Opportunities

    The inactivated vaccines market covered in this report is segmented –

    1) By Type: Viral Vaccine, Bacterial Vaccine

    2) By Method Of Inactivation: Solvent Detergent, Radiation, pH Concentration, Heat Inactivation, Other Methods Of Inactivation

    3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Other Distribution Channels

    Subsegments:

    1) By Viral Vaccine: Inactivated Poliovirus Vaccine (IPV), Inactivated Influenza Vaccine, Inactivated Hepatitis A Vaccine, Inactivated Rabies Vaccine

    2) By Bacterial Vaccine: Inactivated Typhoid Vaccine, Inactivated Cholera Vaccine, Inactivated Pertussis Vaccine, Inactivated Plague Vaccine

    Inactivated Vaccines Market Transformation Trends: What Innovations Are Driving Change?

    Major companies operating in the inactivated vaccines market are concentrating on expanding their product launches and securing regulatory approvals to strengthen their global vaccine portfolios and meet increasing immunization requirements. For instance, in April 2024, Sanofi S.A., a France-based healthcare company, introduced Verorab, its inactivated rabies vaccine, in the UK, suitable for all age groups in both pre-exposure and post-exposure situations. This introduction highlights the company’s ongoing commitment to expanding its range of inactivated vaccines and enhancing its global immunization offerings. This initiative also reflects growing investments and increasing regulatory momentum surrounding inactivated vaccine development and approvals. As more companies advance similar products and diversify their portfolios, these strategic actions are collectively driving significant growth in the inactivated vaccines market, supporting broader protection against infectious diseases.

    Inactivated Vaccines Market Key Players: Which Companies Lead Industry Competition?

    Major companies operating in the inactivated vaccines market are Pfizer Inc., Sinopharm Group Co. Ltd., Merck & Co. Inc., Sanofi S.A., GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, CSL Limited, Daiichi Sankyo Company Limited, Zydus Lifesciences Ltd., Sinovac Biotech Ltd., Biological E Limited, Hualan Biological Engineering Inc., Shenzhen Kangtai Biological Products Co. Ltd., Serum Institute of India Pvt. Ltd., Beijing Tiatan Biological Products Co. Ltd., Valneva SE, Beijing Minhai Biotechnology Co. Ltd., Bharat Biotech International Limited, Panacea Biotec Ltd., Sinergium Biotech SA, Bharat Immunologicals and Biologicals Corporation Limited, Haffkine Biopharmaceutical Corporation Limited, Incepta Vaccine Ltd., Changchun BCHT Biotechnology Co. Ltd.

    View The Full Inactivated Vaccines Market Report:

    https://thebusinessresearchcompany.com/report/inactivated-vaccines-global-market-report?utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

    Inactivated Vaccines Market Regional Split: Which Areas Are Fueling Growth?

    North America was the largest region in the inactivated vaccines market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the inactivated vaccines market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Reach Out To Our Team:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas: +1 310-496-7795

    Asia: +44 7882 955267 & +91 8897263534

    Europe: +44 7882 955267

    Email us at: marketing@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Inactivated Vaccines Market Outlook Highlights The Next Major Growth Opportunities

    Inactivated Vaccines Market Outlook Highlights The Next Major Growth Opportunities

    Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.

    Inactivated Vaccines Market Forecast: What Market Value Is Expected By 2030?

    The market for inactivated vaccines has experienced consistent expansion in recent times. Valued at $6.37 billion in 2025, it is projected to reach $6.61 billion by 2026, reflecting a compound annual growth rate (CAGR) of 3.9%. Historical growth has been driven by several factors, including an increase in the prevalence of infectious diseases, progress in the field of virology research, financial backing from governments for immunization efforts, the broadening of healthcare facilities, and initiatives aimed at raising public awareness about the importance of vaccination.

    The market for inactivated vaccines is projected to experience robust expansion over the coming years. By 2030, its value is anticipated to reach $8.07 billion, reflecting a compound annual growth rate (CAGR) of 5.1%. This forecasted growth is driven by several factors, including a rising elderly population, improved healthcare access in emerging economies, technological progress in vaccine delivery methods, a surge in worldwide immunization efforts, and the growing use of multi-dose and combination vaccines. Key trends shaping this period involve innovations in vaccine formulation, enhanced cold chain infrastructure, a heightened need for pediatric vaccines, strengthened government-backed immunization programs, and the creation of novel combination vaccines.

    Download A Free Sample Report For Comprehensive Market Insights:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=13018&type=smp&utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

    Inactivated Vaccines Market Growth Drivers And Industry Catalysts

    The growing incidence of infectious diseases is anticipated to drive the expansion of the inactivated vaccine market in the coming years. Infectious diseases refer to illnesses caused by pathogens like bacteria, viruses, fungi, or parasites, which can be transmitted between individuals, leading to various symptoms and health issues. Tuberculosis serves as an example of such an infectious disease. Inactivated vaccines utilize non-living pathogens to trigger an immune response, offering effective protection against conditions such as polio, hepatitis A, and influenza. For example, in November 2023, an article from the Centers for Disease Control and Prevention, a U.S.-based national public health agency, reported that tuberculosis cases in the United States rose from 8,320 in 2022 to 9,615 in 2023, reflecting an increase of 1,295 cases. Consequently, the rising prevalence of infectious diseases is fueling growth in the inactivated vaccine market.

    Inactivated Vaccines Market Segment Analysis Highlighting Growth Areas

    The inactivated vaccines market covered in this report is segmented –

    1) By Type: Viral Vaccine, Bacterial Vaccine

    2) By Method Of Inactivation: Solvent Detergent, Radiation, pH Concentration, Heat Inactivation, Other Methods Of Inactivation

    3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Other Distribution Channels

    Subsegments:

    1) By Viral Vaccine: Inactivated Poliovirus Vaccine (IPV), Inactivated Influenza Vaccine, Inactivated Hepatitis A Vaccine, Inactivated Rabies Vaccine

    2) By Bacterial Vaccine: Inactivated Typhoid Vaccine, Inactivated Cholera Vaccine, Inactivated Pertussis Vaccine, Inactivated Plague Vaccine

    Inactivated Vaccines Market Trends Influencing Long-Term Demand

    Key players in the inactivated vaccines industry are prioritizing product introductions and clearance from regulators to reinforce their worldwide vaccine pipelines and address the growing demand for immunization services. To illustrate, in April 2024, Sanofi S.A., a healthcare firm based in France, rolled out Verorab, its inactivated rabies shot, across the UK for all age categories, applicable to both pre-exposure and post-exposure scenarios. This release underscores the organization’s sustained dedication to broadening its catalog of inactivated vaccines and boosting its international immunization capabilities. Furthermore, it signals heightened financial commitments and accelerating regulatory efforts related to the creation and endorsement of inactivated vaccines. With an increasing number of companies pushing similar products forward and expanding their inventories, these coordinated actions are fueling notable expansion in the inactivated vaccines sector, thereby fostering improved protection against infectious illnesses.

    Inactivated Vaccines Market Leading Companies: Who Holds Significant Market Presence?

    Major companies operating in the inactivated vaccines market are Pfizer Inc., Sinopharm Group Co. Ltd., Merck & Co. Inc., Sanofi S.A., GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, CSL Limited, Daiichi Sankyo Company Limited, Zydus Lifesciences Ltd., Sinovac Biotech Ltd., Biological E Limited, Hualan Biological Engineering Inc., Shenzhen Kangtai Biological Products Co. Ltd., Serum Institute of India Pvt. Ltd., Beijing Tiatan Biological Products Co. Ltd., Valneva SE, Beijing Minhai Biotechnology Co. Ltd., Bharat Biotech International Limited, Panacea Biotec Ltd., Sinergium Biotech SA, Bharat Immunologicals and Biologicals Corporation Limited, Haffkine Biopharmaceutical Corporation Limited, Incepta Vaccine Ltd., Changchun BCHT Biotechnology Co. Ltd.

    Access The Complete Inactivated Vaccines Market Report:

    https://www.thebusinessresearchcompany.com/report/inactivated-vaccines-global-market-report?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

    Inactivated Vaccines Market Geographic Landscape: Which Region Dominates Industry Growth?

    North America was the largest region in the inactivated vaccines market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the inactivated vaccines market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test

    Americas: +1 310-496-7795

    Asia: +44 7882 955267 & +91 8897263534

    Europe: +44 7882 955267

    Email us at: marketing@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Rising Prevalence Of Infectious Diseases Boost Inactivated Vaccines Market In Combating Diseases Is Supporting Development Across The Inactivated Vaccines Market

    Rising Prevalence Of Infectious Diseases Boost Inactivated Vaccines Market In Combating Diseases Is Supporting Development Across The Inactivated Vaccines Market

    The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

    What Increase In Market Value Is Predicted For The Inactivated Vaccines Market During The 2026–2030 Period?

    The inactivated vaccines market size has experienced consistent growth in recent years. It is anticipated to expand from $6.37 billion in 2025 to $6.61 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 3.9%. This historical growth can be attributed to factors such as an increasing incidence of infectious diseases, advancements in virology research, government funding allocated for immunization, the expansion of healthcare infrastructure, and public awareness campaigns promoting vaccination.

    The inactivated vaccines market is anticipated to experience robust expansion over the coming years. It is projected to reach $8.07 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 5.1%. This growth during the forecast period can be attributed to an increasing geriatric population, enhanced healthcare access in emerging markets, technological advancements in vaccine delivery systems, a rise in global immunization initiatives, and the greater adoption of multi-dose and combination vaccines. Key trends anticipated in this period include advancements in vaccine formulation, the expansion of cold chain logistics, a growing demand for pediatric vaccines, an increase in government immunization programs, and the development of combination vaccines.

    Download A Free Sample Report For Comprehensive Market Insights:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=13018&type=smp

    What Primary Factors Are Fueling The Expansion Of The Inactivated Vaccines Market?

    The rising occurrence of infectious diseases is anticipated to boost the expansion of the inactivated vaccine market moving forward. These diseases are conditions initiated by pathogens such as bacteria, viruses, fungi, or parasites, capable of spreading between individuals and causing a broad spectrum of symptoms and health complications. Tuberculosis serves as an example of an infectious disease. Inactivated vaccines operate by employing non-living pathogens to induce an immune response, effectively preventing diseases like polio, hepatitis A, and influenza. For illustration, an article released by the Centers for Disease Control and Prevention, a US-based national public health agency, in November 2023, indicated that the count of tuberculosis patients in the USA climbed from 8,320 in 2022 to 9,615 in 2023, signifying an increase of 1,295 cases. Hence, the increasing prevalence of infectious diseases is a key factor driving the growth of the inactivated vaccine market.

    How Are Different Segment Groups Identified Within The Inactivated Vaccines Market?

    The inactivated vaccines market covered in this report is segmented –

    1) By Type: Viral Vaccine, Bacterial Vaccine

    2) By Method Of Inactivation: Solvent Detergent, Radiation, pH Concentration, Heat Inactivation, Other Methods Of Inactivation

    3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Other Distribution Channels

    Subsegments:

    1) By Viral Vaccine: Inactivated Poliovirus Vaccine (IPV), Inactivated Influenza Vaccine, Inactivated Hepatitis A Vaccine, Inactivated Rabies Vaccine

    2) By Bacterial Vaccine: Inactivated Typhoid Vaccine, Inactivated Cholera Vaccine, Inactivated Pertussis Vaccine, Inactivated Plague Vaccine

    Which Trends Are Shaping The Inactivated Vaccines Market Landscape?

    Major companies operating in the inactivated vaccines market are concentrating on extending product launches and securing regulatory clearances to bolster their global vaccine portfolios and satisfy increasing immunization requirements. For instance, in April 2024, Sanofi S.A., a France-based healthcare company, introduced Verorab, its inactivated rabies vaccine, in the UK for use across all age groups in both pre-exposure and post-exposure situations. This launch highlights the company’s ongoing efforts to broaden its range of inactivated vaccines and strengthen its global immunization offerings. The move also reflects increasing investments and rising regulatory momentum surrounding inactivated vaccine development and approvals. As more companies advance similar products and broaden their portfolios, these strategic initiatives are collectively driving significant growth in the inactivated vaccines market, supporting wider protection against infectious diseases.

    Who Are The Leading Firms Participating In The Inactivated Vaccines Market?

    Major companies operating in the inactivated vaccines market are Pfizer Inc., Sinopharm Group Co. Ltd., Merck & Co. Inc., Sanofi S.A., GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, CSL Limited, Daiichi Sankyo Company Limited, Zydus Lifesciences Ltd., Sinovac Biotech Ltd., Biological E Limited, Hualan Biological Engineering Inc., Shenzhen Kangtai Biological Products Co. Ltd., Serum Institute of India Pvt. Ltd., Beijing Tiatan Biological Products Co. Ltd., Valneva SE, Beijing Minhai Biotechnology Co. Ltd., Bharat Biotech International Limited, Panacea Biotec Ltd., Sinergium Biotech SA, Bharat Immunologicals and Biologicals Corporation Limited, Haffkine Biopharmaceutical Corporation Limited, Incepta Vaccine Ltd., Changchun BCHT Biotechnology Co. Ltd.

    Access The Complete Inactivated Vaccines Market Report:

    https://www.thebusinessresearchcompany.com/report/inactivated-vaccines-global-market-report

    Which Region Is The Primary Market For The Inactivated Vaccines Market?

    North America was the largest region in the inactivated vaccines market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the inactivated vaccines market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Access Inactivated Vaccines Market Report for Deeper Competitive Insights

    https://www.thebusinessresearchcompany.com/sample.aspx?id=13018&type=smp

    Browse Through More Reports Similar to the Global Inactivated Vaccines Market 2026, By The Business Research Company

    Inactivated Vaccines Market Report 2026

    https://www.thebusinessresearchcompany.com/report/inactivated-vaccines-global-market-report

    Vaccines Market Report 2026

    https://www.thebusinessresearchcompany.com/report/vaccines-global-market-report

    Therapeutic Bcg Vaccines Market Report 2026

    https://www.thebusinessresearchcompany.com/report/therapeutic-bcg-vaccines-global-market-report

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas: +1 310-496-7795

    Asia: +44 7882 955267 & +91 8897263534

    Europe: +44 7882 955267

    Email us at: marketing@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Inactivated Vaccines Market Forecast Through 2030 With Insights On Market Patterns And Developments

    Inactivated Vaccines Market Forecast Through 2030 With Insights On Market Patterns And Developments

    The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

    How Much Growth In Market Value Is Expected For The Inactivated Vaccines Market Between 2026 And 2030?

    The inactivated vaccines market has shown consistent expansion in recent years. Its size is anticipated to expand from $6.37 billion in 2025 to $6.61 billion in 2026, achieving a compound annual growth rate (CAGR) of 3.9%. This past growth can be ascribed to an increase in the incidence of infectious diseases, advances in virology research, government support for immunization, the broadening of healthcare infrastructure, and public awareness campaigns promoting vaccination.

    The inactivated vaccines market is projected to experience robust expansion over the coming years. This market is set to reach $8.07 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 5.1%. Factors contributing to this anticipated growth include an expanding elderly demographic, improved healthcare accessibility in developing economies, innovations in vaccine administration methods, a surge in worldwide immunization efforts, and the increasing use of multi-dose and combination vaccines. Key trends foreseen for this period encompass improvements in vaccine composition, the broadening of cold chain infrastructure, a rising need for childhood vaccines, the expansion of governmental immunization schemes, and the ongoing creation of combination vaccines.

    Access Your Free Sample Report For In-Depth Market Analysis:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=13018&type=smp

    What Leading Drivers Are Supporting The Inactivated Vaccines Market Expansion?

    The expanding occurrence of infectious diseases is projected to stimulate the growth of the inactivated vaccine market in the foreseeable future. These diseases are ailments stemming from pathogens such as bacteria, viruses, fungi, or parasites, which are transmissible between individuals, leading to diverse symptoms and health complications. Tuberculosis is a form of infectious disease. Inactivated vaccines leverage non-living pathogens to trigger an immune response, effectively averting conditions like polio, hepatitis A, and influenza. For example, a report from November 2023 by the Centers for Disease Control and Prevention, a US-based national public health agency, indicated that the count of tuberculosis patients in the USA climbed from 8,320 in 2022 to 9,615 in 2023, marking an increase of 1,295 cases. Hence, the escalating prevalence of infectious diseases is fueling the growth of the inactivated vaccine market.

    How Are Different Segments Classified In The Inactivated Vaccines Market Segment Analysis?

    The inactivated vaccines market covered in this report is segmented –

    1) By Type: Viral Vaccine, Bacterial Vaccine

    2) By Method Of Inactivation: Solvent Detergent, Radiation, pH Concentration, Heat Inactivation, Other Methods Of Inactivation

    3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Other Distribution Channels

    Subsegments:

    1) By Viral Vaccine: Inactivated Poliovirus Vaccine (IPV), Inactivated Influenza Vaccine, Inactivated Hepatitis A Vaccine, Inactivated Rabies Vaccine

    2) By Bacterial Vaccine: Inactivated Typhoid Vaccine, Inactivated Cholera Vaccine, Inactivated Pertussis Vaccine, Inactivated Plague Vaccine

    What Trends Are Shaping The Future Of The Inactivated Vaccines Market?

    Major companies operating in the inactivated vaccines market are concentrating on expanding product launches and securing regulatory approvals to bolster their global vaccine portfolios and address increasing immunization requirements. For instance, in April 2024, Sanofi S.A., a France-based healthcare company, introduced Verorab, its inactivated rabies vaccine, in the UK, making it available for all age groups in both pre-exposure and post-exposure circumstances. This launch emphasizes the company’s sustained efforts to broaden its range of inactivated vaccines and strengthen its global immunization offerings. The development also indicates rising investments and increasing regulatory momentum around inactivated vaccine development and approvals. As more companies advance similar products and diversify their portfolios, these strategic initiatives are collectively fostering substantial growth in the inactivated vaccines market, supporting broader protection against infectious diseases.

    Who Are The Companies Driving Activity In The Inactivated Vaccines Market?

    Major companies operating in the inactivated vaccines market are Pfizer Inc., Sinopharm Group Co. Ltd., Merck & Co. Inc., Sanofi S.A., GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, CSL Limited, Daiichi Sankyo Company Limited, Zydus Lifesciences Ltd., Sinovac Biotech Ltd., Biological E Limited, Hualan Biological Engineering Inc., Shenzhen Kangtai Biological Products Co. Ltd., Serum Institute of India Pvt. Ltd., Beijing Tiatan Biological Products Co. Ltd., Valneva SE, Beijing Minhai Biotechnology Co. Ltd., Bharat Biotech International Limited, Panacea Biotec Ltd., Sinergium Biotech SA, Bharat Immunologicals and Biologicals Corporation Limited, Haffkine Biopharmaceutical Corporation Limited, Incepta Vaccine Ltd., Changchun BCHT Biotechnology Co. Ltd.

    Get The Full Inactivated Vaccines Market Report:

    https://www.thebusinessresearchcompany.com/report/inactivated-vaccines-global-market-report

    Which Region Is The Top Contributor To The Inactivated Vaccines Market By Share?

    North America was the largest region in the inactivated vaccines market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the inactivated vaccines market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Request A Customized Inactivated Vaccines Market Report For Competitive Insights:

    https://www.thebusinessresearchcompany.com/report/inactivated-vaccines-global-market-report

    Browse Through More Reports Similar to the Global Inactivated Vaccines Market 2026, By The Business Research Company

    Inactivated Vaccines Market Report 2026

    https://www.thebusinessresearchcompany.com/report/inactivated-vaccines-global-market-report

    Vaccines Market Report 2026

    https://www.thebusinessresearchcompany.com/report/vaccines-global-market-report

    Therapeutic Bcg Vaccines Market Report 2026

    https://www.thebusinessresearchcompany.com/report/therapeutic-bcg-vaccines-global-market-report

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Asia +44 7882 955267 & +91 8897263534

    Europe +44 7882 955267

    Email us at: marketing@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Inactivated Vaccines Market Growth Outlook 2026–2030 with Innovation Trends and Competitive Analysis

    Inactivated Vaccines Market Growth Outlook 2026–2030 with Innovation Trends and Competitive Analysis

    The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

    What Is The Forecasted Market Value Of The Inactivated Vaccines Market Across 2026–2030?

    The inactivated vaccines market size has seen consistent expansion in recent years. It is projected to increase from $6.37 billion in 2025 to $6.61 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 3.9%. This historical growth can be ascribed to the escalating occurrence of infectious diseases, developments in virology research, governmental financial support for immunization, the broadening of healthcare infrastructure, and public information campaigns for vaccination.

    The inactivated vaccines market is projected to experience substantial expansion in the coming years, with its valuation set to reach $8.07 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 5.1%. This anticipated growth is primarily driven by factors such as an expanding elderly demographic, enhanced healthcare accessibility within emerging markets, innovations in vaccine delivery mechanisms, a surge in worldwide immunization efforts, and the increasing uptake of multi-dose and combination vaccines. Key developments expected during this period involve progress in vaccine formulation, the broadening of cold chain logistics, a rising need for pediatric vaccines, an increase in governmental immunization schemes, and the ongoing creation of combination vaccines.

    Download the Free Sample Report to Explore Key Market Insights:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=13018&type=smp

    What Drivers Are Shaping The Future Growth Of The Inactivated Vaccines Market?

    The increasing prevalence of infectious diseases is projected to drive the growth of the inactivated vaccine market moving forward. Infectious diseases are conditions caused by pathogens such as bacteria, viruses, fungi, or parasites that can spread between individuals, resulting in diverse symptoms and health complications, with tuberculosis being one such example. Inactivated vaccines work by employing non-living pathogens to stimulate an immune response, effectively preventing diseases like polio, hepatitis A, and influenza. For instance, in November 2023, data from an article published by the Centers for Disease Control and Prevention, a US-based national public health agency, revealed that the number of tuberculosis patients in the USA escalated from 8,320 in 2022 to 9,615 in 2023, signifying an increase of 1,295 cases. Consequently, the rising occurrence of infectious diseases is fueling the expansion of the inactivated vaccine market.

    What Segmentation Levels Are Considered In The Inactivated Vaccines Market?

    The inactivated vaccines market covered in this report is segmented –

    1) By Type: Viral Vaccine, Bacterial Vaccine

    2) By Method Of Inactivation: Solvent Detergent, Radiation, pH Concentration, Heat Inactivation, Other Methods Of Inactivation

    3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Other Distribution Channels

    Subsegments:

    1) By Viral Vaccine: Inactivated Poliovirus Vaccine (IPV), Inactivated Influenza Vaccine, Inactivated Hepatitis A Vaccine, Inactivated Rabies Vaccine

    2) By Bacterial Vaccine: Inactivated Typhoid Vaccine, Inactivated Cholera Vaccine, Inactivated Pertussis Vaccine, Inactivated Plague Vaccine

    What Trends Are Projected To Affect The Inactivated Vaccines Market?

    Major companies operating in the inactivated vaccines market are focusing on increasing product launches and securing regulatory approvals to enhance their global vaccine portfolios and address growing immunization needs. For instance, in April 2024, Sanofi S.A., a France-based healthcare company, introduced Verorab, its inactivated rabies vaccine, in the UK for use across all age groups in both pre-exposure and post-exposure situations. This launch highlights the company’s ongoing dedication to expanding its range of inactivated vaccines and strengthening its global immunization offerings. The move also reflects increasing investments and rising regulatory momentum surrounding inactivated vaccine development and approvals. As more companies advance similar products and broaden their portfolios, these strategic initiatives are collectively driving significant growth in the inactivated vaccines market, supporting wider protection against infectious diseases.

    Which Leading Firms Are Contributing To The Growth Of The Inactivated Vaccines Market?

    Major companies operating in the inactivated vaccines market are Pfizer Inc., Sinopharm Group Co. Ltd., Merck & Co. Inc., Sanofi S.A., GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, CSL Limited, Daiichi Sankyo Company Limited, Zydus Lifesciences Ltd., Sinovac Biotech Ltd., Biological E Limited, Hualan Biological Engineering Inc., Shenzhen Kangtai Biological Products Co. Ltd., Serum Institute of India Pvt. Ltd., Beijing Tiatan Biological Products Co. Ltd., Valneva SE, Beijing Minhai Biotechnology Co. Ltd., Bharat Biotech International Limited, Panacea Biotec Ltd., Sinergium Biotech SA, Bharat Immunologicals and Biologicals Corporation Limited, Haffkine Biopharmaceutical Corporation Limited, Incepta Vaccine Ltd., Changchun BCHT Biotechnology Co. Ltd.

    Read the full inactivated vaccines market report here:

    https://www.thebusinessresearchcompany.com/report/inactivated-vaccines-global-market-report

    Which Geographic Regions Are Influencing Demand In The Inactivated Vaccines Market?

    North America was the largest region in the inactivated vaccines market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the inactivated vaccines market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Request A Tailored Inactivated Vaccines Market Research Report For Competitive Advantage:

    https://www.thebusinessresearchcompany.com/customise?id=13018&type=smp

    Browse Through More Reports Similar to the Global Inactivated Vaccines Market 2026, By The Business Research Company

    Inactivated Vaccines Market Report 2026

    https://www.thebusinessresearchcompany.com/report/inactivated-vaccines-global-market-report

    Vaccines Market Report 2026

    https://www.thebusinessresearchcompany.com/report/vaccines-global-market-report

    Therapeutic Bcg Vaccines Market Report 2026

    https://www.thebusinessresearchcompany.com/report/therapeutic-bcg-vaccines-global-market-report

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Asia +44 7882 955267 & +91 8897263534

    Europe +44 7882 955267

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Inactivated Vaccines Global Forecast: Market to Scale Up to $8.07 Billion by 2030 at 5.1% CAGR

    Inactivated Vaccines Global Forecast: Market to Scale Up to $8.07 Billion by 2030 at 5.1% CAGR

    Uncover key drivers, emerging technologies, and competitive movements shaping the inactivated vaccines market from 2026–2035 with trusted insights from The Business Research Company

    What size range is anticipated for the Inactivated Vaccines Market from 2026 to 2030?

    The inactivated vaccines market has demonstrated steady growth in size over recent years. It is anticipated to grow from $6.37 billion in 2025 to $6.61 billion in 2026, with a compound annual growth rate (CAGR) of 3.9%. This past growth can be attributed to an increasing prevalence of infectious diseases, advancements in virology research, government funding for immunization efforts, the expansion of healthcare infrastructure, and public awareness campaigns promoting vaccination.

    The inactivated vaccines market is projected to experience substantial expansion over the forthcoming years. This market is anticipated to reach $8.07 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 5.1%. Factors contributing to this growth during the forecast period include a rising elderly population, improved healthcare accessibility in emerging markets, progress in vaccine delivery technologies, a surge in worldwide immunization efforts, and the increasing use of multi-dose and combination vaccines. Key trends for the forecast period encompass innovations in vaccine formulation, the broadening of cold chain logistics, a heightened demand for pediatric vaccines, the expansion of governmental immunization programs, and the creation of combination vaccines.

    Access Your Free Sample Report for In-Depth Market Insights:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=13018&type=smp

    What Drivers Are Affecting Demand In The Inactivated Vaccines Market?

    The expanding occurrence of infectious diseases is anticipated to boost the development of the inactivated vaccine market in the future. These illnesses originate from pathogens like bacteria, viruses, fungi, or parasites, which are transmissible between individuals and lead to diverse symptoms and health issues. Tuberculosis represents a form of infectious disease. Non-living pathogens are employed in inactivated vaccines to trigger an immune response, thereby preventing conditions like polio, hepatitis A, and influenza. For example, as reported by an article from the US-based national public health agency, Centers for Disease Control and Prevention, in November 2023, the count of tuberculosis patients in the USA rose from 8,320 in 2022 to 9,615 in 2023, marking an increment of 1,295 cases. Consequently, the rising occurrence of infectious diseases is stimulating the expansion of the inactivated vaccine market.

    Which Segment Groups Are Influencing The Inactivated Vaccines Market?

    The inactivated vaccines market covered in this report is segmented –

    1) By Type: Viral Vaccine, Bacterial Vaccine

    2) By Method Of Inactivation: Solvent Detergent, Radiation, pH Concentration, Heat Inactivation, Other Methods Of Inactivation

    3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Other Distribution Channels

    Subsegments:

    1) By Viral Vaccine: Inactivated Poliovirus Vaccine (IPV), Inactivated Influenza Vaccine, Inactivated Hepatitis A Vaccine, Inactivated Rabies Vaccine

    2) By Bacterial Vaccine: Inactivated Typhoid Vaccine, Inactivated Cholera Vaccine, Inactivated Pertussis Vaccine, Inactivated Plague Vaccine

    What Upcoming Trends Are Likely To Define The Future Path Of The Inactivated Vaccines Market?

    Leading companies in the inactivated vaccines market are concentrating on increasing product introductions and acquiring regulatory clearances to bolster their global vaccine collections and satisfy increasing immunization demands. For instance, in April 2024, Sanofi S.A., a healthcare firm based in France, launched Verorab, its inactivated rabies vaccine, in the UK, suitable for all age groups in both pre-exposure and post-exposure scenarios. This introduction emphasizes the company’s continuous efforts to expand its assortment of inactivated vaccines and reinforce its worldwide immunization provisions. The action further reflects escalating investments and growing regulatory drive surrounding the development and approval of inactivated vaccines. As more companies advance similar products and diversify their portfolios, these calculated strategies are collectively fostering significant expansion within the inactivated vaccines market, supporting broader protection against infectious diseases.

    Who Are The Primary Competitors In The Global Inactivated Vaccines Market?

    Major companies operating in the inactivated vaccines market are Pfizer Inc., Sinopharm Group Co. Ltd., Merck & Co. Inc., Sanofi S.A., GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, CSL Limited, Daiichi Sankyo Company Limited, Zydus Lifesciences Ltd., Sinovac Biotech Ltd., Biological E Limited, Hualan Biological Engineering Inc., Shenzhen Kangtai Biological Products Co. Ltd., Serum Institute of India Pvt. Ltd., Beijing Tiatan Biological Products Co. Ltd., Valneva SE, Beijing Minhai Biotechnology Co. Ltd., Bharat Biotech International Limited, Panacea Biotec Ltd., Sinergium Biotech SA, Bharat Immunologicals and Biologicals Corporation Limited, Haffkine Biopharmaceutical Corporation Limited, Incepta Vaccine Ltd., Changchun BCHT Biotechnology Co. Ltd.

    Access The Complete Report For Deeper Market Insights:

    https://www.thebusinessresearchcompany.com/report/inactivated-vaccines-global-market-report

    Which Global Regions Are Shaping The Competitive Landscape Of The Inactivated Vaccines Market?

    North America was the largest region in the inactivated vaccines market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the inactivated vaccines market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Request Your Customized Inactivated Vaccines Market Research Report for Competitive Advantage:

    https://www.thebusinessresearchcompany.com/customise?id=13018&type=smp

    Browse Through More Reports Similar to the Global Inactivated Vaccines Market 2026, By The Business Research Company

    Inactivated Vaccines Market Report 2026

    https://www.thebusinessresearchcompany.com/report/inactivated-vaccines-global-market-report

    Vaccines Market Report 2026

    https://www.thebusinessresearchcompany.com/report/vaccines-global-market-report

    Therapeutic Bcg Vaccines Market Report 2026

    https://www.thebusinessresearchcompany.com/report/therapeutic-bcg-vaccines-global-market-report

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Asia +44 7882 955267 & +91 8897263534

    Europe +44 7882 955267

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Global Inactivated Vaccines Market Size and Forecast to 2029: Revenue, Growth, and Trends

    Global Inactivated Vaccines Market Size and Forecast to 2029: Revenue, Growth, and Trends

    Uncover key drivers, emerging technologies, and competitive movements shaping the inactivated vaccines market from 2025–2034 with trusted insights from The Business Research Company

    How Big Is The Inactivated Vaccines Market Size Today And What Will Its Value Be At The End Of 2029?

    The inactivated vaccines market has shown consistent expansion in its size during recent years. Its value is anticipated to rise from $6.19 billion in 2024 to $6.37 billion in 2025, reflecting a compound annual growth rate (CAGR) of 2.8%. Factors contributing to this growth historically include polio eradication efforts, influenza vaccination programs, the emergence of infectious diseases, and various regulatory approvals.

    The inactivated vaccines market size is projected to experience consistent expansion over the upcoming years. This market is anticipated to reach $7.58 billion by 2029, demonstrating a compound annual growth rate (CAGR) of 4.5%. Key factors driving this growth during the forecast period include efforts in pandemic preparedness, the widening scope of vaccine coverage, progress in biomanufacturing, and various health equity initiatives. Significant trends observed during this period encompass mrna vaccine platforms, the development of combination vaccines, thermostable vaccine technologies, and the implementation of digital vaccine passports.

    Access A Free Sample Of The Report:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=13018&type=smp

    Which Key Drivers Are Powering Growth In The Inactivated Vaccines Market?

    The inactivated vaccine market is anticipated to expand due to the rising occurrence of infectious diseases. These illnesses, characterized by their person-to-person spread, stem from pathogens like bacteria, viruses, fungi, or parasites, manifesting in diverse symptoms and health issues. Tuberculosis represents one form of infectious disease. Inactivated vaccines function by employing non-living pathogens to induce an immune response, thereby offering effective prevention against conditions like polio, hepatitis A, and influenza. To illustrate, data from November 2023, published by the US-based national public health agency, Centers for Disease Control and Prevention, showed a rise in tuberculosis cases within the USA, climbing from 8,320 in 2022 to 9,615 in 2023, signifying an increase of 1,295 cases. Consequently, the increasing prevalence of infectious diseases is a significant driver for the growth of the inactivated vaccine market.

    Which Segment Categories Are Driving Maximum Growth In The Inactivated Vaccines Market?

    The inactivated vaccines market covered in this report is segmented –

    1) By Type: Viral Vaccine, Bacterial Vaccine

    2) By Method Of Inactivation: Solvent Detergent, Radiation, pH Concentration, Heat Inactivation, Other Methods Of Inactivation

    3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Other Distribution Channels

    Subsegments:

    1) By Viral Vaccine: Inactivated Poliovirus Vaccine (IPV), Inactivated Influenza Vaccine, Inactivated Hepatitis A Vaccine, Inactivated Rabies Vaccine

    2) By Bacterial Vaccine: Inactivated Typhoid Vaccine, Inactivated Cholera Vaccine, Inactivated Pertussis Vaccine, Inactivated Plague Vaccine

    What Key Trends Are Driving Growth In The Inactivated Vaccines Market?

    Leading firms within the inactivated vaccines market are launching novel and sophisticated inactivated vaccines to maintain their competitive standing. An inactivated vaccine comprises virus particles, bacteria, or other pathogens that have been cultured and then rendered inactive, thereby eliminating their capacity to cause disease. For example, in January 2022, UK-based pharmaceutical and biotechnology company GSK PLC introduced Shingrix, a new inactivated vaccine designed to protect against shingles (Herpes zoster). Shingrix is a non-live, recombinant subunit adjuvanted vaccine administered intramuscularly in two doses. Initially, the vaccine was indicated for individuals 50 years and older. More recently, its scope has been broadened to include individuals 18 and older who are at increased risk of developing shingles because of immunodeficiency or immunosuppression resulting from a known disease or medical treatment.

    Who Are The Leading Companies Driving The Inactivated Vaccines Market?

    Major companies operating in the inactivated vaccines market are Pfizer Inc., Johnson & Johnson Services Inc., Sinopharm Group Co. Ltd., Merck & Co. Inc., Sanofi S.A., GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Astellas Pharma Inc., CSL Limited, Daiichi Sankyo Company Limited, Mitsubishi Tanabe Pharma Corporation, Novavax Inc., Zydus Lifesciences Ltd., Sinovac Biotech Ltd., Biological E Limited, Hualan Biological Engineering Inc., CanSino Biologics Inc., Shenzhen Kangtai Biological Products Co. Ltd., Serum Institute of India Pvt. Ltd., Beijing Tiatan Biological Products Co. Ltd., Valneva SE, Bavarian Nordic A/S., Beijing Minhai Biotechnology Co. Ltd., Bharat Biotech International Limited, Panacea Biotec Ltd., Sinergium Biotech SA, Bharat Immunologicals and Biologicals Corporation Limited, Haffkine Biopharmaceutical Corporation Limited, Incepta Vaccine Ltd., Changchun BCHT Biotechnology Co. Ltd., .

    Download The Full Report Here:

    https://www.thebusinessresearchcompany.com/report/inactivated-vaccines-global-market-report

    Which Region Holds The Largest Share In The Inactivated Vaccines Market Today?

    North America was the largest region in the inactivated vaccines market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in inactivated vaccines market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

    Get A Report Customized For You Here:

    https://www.thebusinessresearchcompany.com/customise?id=13018&type=smp

    Browse Through More Reports Similar to the Global Inactivated Vaccines Market 2025, By The Business Research Company

    Cancer Vaccine Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/cancer-vaccine-global-market-report

    Dtp Vaccine Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/dtp-vaccine-global-market-report

    Companion Animal Veterinary Vaccines Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/companion-animal-veterinary-vaccines-global-market-report

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Asia +44 7882 955267 & +91 8897263534

    Europe +44 7882 955267

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Inactivated Vaccines Market Growth Opportunities: Insights from 2025–2029

    Inactivated Vaccines Market Growth Opportunities: Insights from 2025–2029

    Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

    How Does The Market Size Of The Inactivated Vaccines Industry Compare Between 2025 And 2029?

    The inactivated vaccines market has shown consistent expansion in recent years. Its value is forecast to increase from $6.19 billion in 2024 to $6.37 billion in 2025, reflecting a compound annual growth rate (CAGR) of 2.8%. Historically, this growth has been driven by factors such as polio eradication efforts, influenza vaccination programs, the emergence of infectious diseases, and various regulatory approvals.

    The inactivated vaccines market size is anticipated to experience consistent expansion in the coming years. It is projected to increase to $7.58 billion by 2029, achieving a compound annual growth rate (CAGR) of 4.5%. This growth during the forecast period can be linked to factors such as pandemic preparedness, expanding vaccine coverage, biomanufacturing advancements, and health equity initiatives. Significant trends identified for the forecast period include mrna vaccine platforms, combination vaccines, thermostable vaccines, and digital vaccine passports.

    Unlock Your Free Sample Report for Exclusive Market Data:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=13018&type=smp

    Which Drivers Are Shaping The Inactivated Vaccines Industry’s Market Share?

    The increasing prevalence of infectious diseases is anticipated to fuel the expansion of the inactivated vaccine market moving forward. Infectious diseases are conditions stemming from pathogens such as bacteria, viruses, fungi, or parasites, which are transmissible between individuals and can lead to a diverse range of symptoms and health complications. Tuberculosis represents a form of infectious disease. Inactivated vaccines utilize non-living pathogens to stimulate an immune response, thereby effectively preventing diseases like polio, hepatitis A and influenza. For example, in November 2023, an article published by Centers for Disease Control and Prevention, a US-based national public health agency, indicated that the number of tuberculosis patients in the USA climbed from 8,320 in 2022 to 9,615 in 2023, marking an increase of 1,295 cases. Consequently, the growing occurrence of infectious diseases is propelling the growth of the inactivated vaccine market.

    How Is The Inactivated Vaccines Market Classified Into Different Segments?

    The inactivated vaccines market covered in this report is segmented –

    1) By Type: Viral Vaccine, Bacterial Vaccine

    2) By Method Of Inactivation: Solvent Detergent, Radiation, pH Concentration, Heat Inactivation, Other Methods Of Inactivation

    3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Other Distribution Channels

    Subsegments:

    1) By Viral Vaccine: Inactivated Poliovirus Vaccine (IPV), Inactivated Influenza Vaccine, Inactivated Hepatitis A Vaccine, Inactivated Rabies Vaccine

    2) By Bacterial Vaccine: Inactivated Typhoid Vaccine, Inactivated Cholera Vaccine, Inactivated Pertussis Vaccine, Inactivated Plague Vaccine

    What Trends Are Redefining The Inactivated Vaccines Market Dynamics?

    Leading firms within the inactivated vaccines market are launching novel and sophisticated inactivated vaccines to maintain their competitive standing. An inactivated vaccine is comprised of cultured virus particles, bacteria, or other pathogens that have been rendered inert by killing them to eliminate their capacity to cause disease. For example, in January 2022, GSK PLC, a pharmaceutical and biotechnology firm based in the UK, introduced a novel inactivated vaccination called Shingrix to help protect against shingles (Herpes zoster). Shingrix is a recombinant subunit adjuvanted vaccine that is not live, administered via intramuscular injection in two doses. Initially, the vaccine was indicated for individuals 50 years and older. Its scope has recently broadened to include persons 18 and older who face an elevated risk of developing shingles due to immunodeficiency or immunosuppression stemming from an identified illness or medical treatment.

    Who Are The Major Companies Operating In The Inactivated Vaccines Market?

    Major companies operating in the inactivated vaccines market are Pfizer Inc., Johnson & Johnson Services Inc., Sinopharm Group Co. Ltd., Merck & Co. Inc., Sanofi S.A., GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Astellas Pharma Inc., CSL Limited, Daiichi Sankyo Company Limited, Mitsubishi Tanabe Pharma Corporation, Novavax Inc., Zydus Lifesciences Ltd., Sinovac Biotech Ltd., Biological E Limited, Hualan Biological Engineering Inc., CanSino Biologics Inc., Shenzhen Kangtai Biological Products Co. Ltd., Serum Institute of India Pvt. Ltd., Beijing Tiatan Biological Products Co. Ltd., Valneva SE, Bavarian Nordic A/S., Beijing Minhai Biotechnology Co. Ltd., Bharat Biotech International Limited, Panacea Biotec Ltd., Sinergium Biotech SA, Bharat Immunologicals and Biologicals Corporation Limited, Haffkine Biopharmaceutical Corporation Limited, Incepta Vaccine Ltd., Changchun BCHT Biotechnology Co. Ltd., .

    Download The Full Report For Exclusive Market Findings:

    https://www.thebusinessresearchcompany.com/report/inactivated-vaccines-global-market-report

    What Regional Growth Trends Are Shaping The Inactivated Vaccines Market Outlook?

    North America was the largest region in the inactivated vaccines market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in inactivated vaccines market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

    Request A Customized Version Of The Inactivated Vaccines Market Report:

    https://www.thebusinessresearchcompany.com/customise?id=13018&type=smp

    Browse Through More Reports Similar to the Global Inactivated Vaccines Market 2025, By The Business Research Company

    Cancer Vaccine Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/cancer-vaccine-global-market-report

    Dtp Vaccine Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/dtp-vaccine-global-market-report

    Companion Animal Veterinary Vaccines Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/companion-animal-veterinary-vaccines-global-market-report

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Asia +44 7882 955267 & +91 8897263534

    Europe +44 7882 955267

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Inactivated Vaccines Market Growth Opportunities: Insights from 2025–2029

    Inactivated Vaccines Market Growth Opportunities: Insights from 2025–2029

    Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

    How Does The Market Size Of The Inactivated Vaccines Industry Compare Between 2025 And 2029?

    The inactivated vaccines market has shown consistent expansion in recent years. Its value is forecast to increase from $6.19 billion in 2024 to $6.37 billion in 2025, reflecting a compound annual growth rate (CAGR) of 2.8%. Historically, this growth has been driven by factors such as polio eradication efforts, influenza vaccination programs, the emergence of infectious diseases, and various regulatory approvals.

    The inactivated vaccines market size is anticipated to experience consistent expansion in the coming years. It is projected to increase to $7.58 billion by 2029, achieving a compound annual growth rate (CAGR) of 4.5%. This growth during the forecast period can be linked to factors such as pandemic preparedness, expanding vaccine coverage, biomanufacturing advancements, and health equity initiatives. Significant trends identified for the forecast period include mrna vaccine platforms, combination vaccines, thermostable vaccines, and digital vaccine passports.

    Unlock Your Free Sample Report for Exclusive Market Data:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=13018&type=smp

    Which Drivers Are Shaping The Inactivated Vaccines Industry’s Market Share?

    The increasing prevalence of infectious diseases is anticipated to fuel the expansion of the inactivated vaccine market moving forward. Infectious diseases are conditions stemming from pathogens such as bacteria, viruses, fungi, or parasites, which are transmissible between individuals and can lead to a diverse range of symptoms and health complications. Tuberculosis represents a form of infectious disease. Inactivated vaccines utilize non-living pathogens to stimulate an immune response, thereby effectively preventing diseases like polio, hepatitis A and influenza. For example, in November 2023, an article published by Centers for Disease Control and Prevention, a US-based national public health agency, indicated that the number of tuberculosis patients in the USA climbed from 8,320 in 2022 to 9,615 in 2023, marking an increase of 1,295 cases. Consequently, the growing occurrence of infectious diseases is propelling the growth of the inactivated vaccine market.

    How Is The Inactivated Vaccines Market Classified Into Different Segments?

    The inactivated vaccines market covered in this report is segmented –

    1) By Type: Viral Vaccine, Bacterial Vaccine

    2) By Method Of Inactivation: Solvent Detergent, Radiation, pH Concentration, Heat Inactivation, Other Methods Of Inactivation

    3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Other Distribution Channels

    Subsegments:

    1) By Viral Vaccine: Inactivated Poliovirus Vaccine (IPV), Inactivated Influenza Vaccine, Inactivated Hepatitis A Vaccine, Inactivated Rabies Vaccine

    2) By Bacterial Vaccine: Inactivated Typhoid Vaccine, Inactivated Cholera Vaccine, Inactivated Pertussis Vaccine, Inactivated Plague Vaccine

    What Trends Are Redefining The Inactivated Vaccines Market Dynamics?

    Leading firms within the inactivated vaccines market are launching novel and sophisticated inactivated vaccines to maintain their competitive standing. An inactivated vaccine is comprised of cultured virus particles, bacteria, or other pathogens that have been rendered inert by killing them to eliminate their capacity to cause disease. For example, in January 2022, GSK PLC, a pharmaceutical and biotechnology firm based in the UK, introduced a novel inactivated vaccination called Shingrix to help protect against shingles (Herpes zoster). Shingrix is a recombinant subunit adjuvanted vaccine that is not live, administered via intramuscular injection in two doses. Initially, the vaccine was indicated for individuals 50 years and older. Its scope has recently broadened to include persons 18 and older who face an elevated risk of developing shingles due to immunodeficiency or immunosuppression stemming from an identified illness or medical treatment.

    Who Are The Major Companies Operating In The Inactivated Vaccines Market?

    Major companies operating in the inactivated vaccines market are Pfizer Inc., Johnson & Johnson Services Inc., Sinopharm Group Co. Ltd., Merck & Co. Inc., Sanofi S.A., GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Astellas Pharma Inc., CSL Limited, Daiichi Sankyo Company Limited, Mitsubishi Tanabe Pharma Corporation, Novavax Inc., Zydus Lifesciences Ltd., Sinovac Biotech Ltd., Biological E Limited, Hualan Biological Engineering Inc., CanSino Biologics Inc., Shenzhen Kangtai Biological Products Co. Ltd., Serum Institute of India Pvt. Ltd., Beijing Tiatan Biological Products Co. Ltd., Valneva SE, Bavarian Nordic A/S., Beijing Minhai Biotechnology Co. Ltd., Bharat Biotech International Limited, Panacea Biotec Ltd., Sinergium Biotech SA, Bharat Immunologicals and Biologicals Corporation Limited, Haffkine Biopharmaceutical Corporation Limited, Incepta Vaccine Ltd., Changchun BCHT Biotechnology Co. Ltd., .

    Download The Full Report For Exclusive Market Findings:

    https://www.thebusinessresearchcompany.com/report/inactivated-vaccines-global-market-report

    What Regional Growth Trends Are Shaping The Inactivated Vaccines Market Outlook?

    North America was the largest region in the inactivated vaccines market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in inactivated vaccines market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

    Request A Customized Version Of The Inactivated Vaccines Market Report:

    https://www.thebusinessresearchcompany.com/customise?id=13018&type=smp

    Browse Through More Reports Similar to the Global Inactivated Vaccines Market 2025, By The Business Research Company

    Cancer Vaccine Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/cancer-vaccine-global-market-report

    Dtp Vaccine Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/dtp-vaccine-global-market-report

    Companion Animal Veterinary Vaccines Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/companion-animal-veterinary-vaccines-global-market-report

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Asia +44 7882 955267 & +91 8897263534

    Europe +44 7882 955267

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Inactivated Vaccines Market Growth Opportunities: Insights from 2025–2029

    Inactivated Vaccines Market Growth Opportunities: Insights from 2025–2029

    Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

    How Does The Market Size Of The Inactivated Vaccines Industry Compare Between 2025 And 2029?

    The inactivated vaccines market has shown consistent expansion in recent years. Its value is forecast to increase from $6.19 billion in 2024 to $6.37 billion in 2025, reflecting a compound annual growth rate (CAGR) of 2.8%. Historically, this growth has been driven by factors such as polio eradication efforts, influenza vaccination programs, the emergence of infectious diseases, and various regulatory approvals.

    The inactivated vaccines market size is anticipated to experience consistent expansion in the coming years. It is projected to increase to $7.58 billion by 2029, achieving a compound annual growth rate (CAGR) of 4.5%. This growth during the forecast period can be linked to factors such as pandemic preparedness, expanding vaccine coverage, biomanufacturing advancements, and health equity initiatives. Significant trends identified for the forecast period include mrna vaccine platforms, combination vaccines, thermostable vaccines, and digital vaccine passports.

    Unlock Your Free Sample Report for Exclusive Market Data:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=13018&type=smp

    Which Drivers Are Shaping The Inactivated Vaccines Industry’s Market Share?

    The increasing prevalence of infectious diseases is anticipated to fuel the expansion of the inactivated vaccine market moving forward. Infectious diseases are conditions stemming from pathogens such as bacteria, viruses, fungi, or parasites, which are transmissible between individuals and can lead to a diverse range of symptoms and health complications. Tuberculosis represents a form of infectious disease. Inactivated vaccines utilize non-living pathogens to stimulate an immune response, thereby effectively preventing diseases like polio, hepatitis A and influenza. For example, in November 2023, an article published by Centers for Disease Control and Prevention, a US-based national public health agency, indicated that the number of tuberculosis patients in the USA climbed from 8,320 in 2022 to 9,615 in 2023, marking an increase of 1,295 cases. Consequently, the growing occurrence of infectious diseases is propelling the growth of the inactivated vaccine market.

    How Is The Inactivated Vaccines Market Classified Into Different Segments?

    The inactivated vaccines market covered in this report is segmented –

    1) By Type: Viral Vaccine, Bacterial Vaccine

    2) By Method Of Inactivation: Solvent Detergent, Radiation, pH Concentration, Heat Inactivation, Other Methods Of Inactivation

    3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Other Distribution Channels

    Subsegments:

    1) By Viral Vaccine: Inactivated Poliovirus Vaccine (IPV), Inactivated Influenza Vaccine, Inactivated Hepatitis A Vaccine, Inactivated Rabies Vaccine

    2) By Bacterial Vaccine: Inactivated Typhoid Vaccine, Inactivated Cholera Vaccine, Inactivated Pertussis Vaccine, Inactivated Plague Vaccine

    What Trends Are Redefining The Inactivated Vaccines Market Dynamics?

    Leading firms within the inactivated vaccines market are launching novel and sophisticated inactivated vaccines to maintain their competitive standing. An inactivated vaccine is comprised of cultured virus particles, bacteria, or other pathogens that have been rendered inert by killing them to eliminate their capacity to cause disease. For example, in January 2022, GSK PLC, a pharmaceutical and biotechnology firm based in the UK, introduced a novel inactivated vaccination called Shingrix to help protect against shingles (Herpes zoster). Shingrix is a recombinant subunit adjuvanted vaccine that is not live, administered via intramuscular injection in two doses. Initially, the vaccine was indicated for individuals 50 years and older. Its scope has recently broadened to include persons 18 and older who face an elevated risk of developing shingles due to immunodeficiency or immunosuppression stemming from an identified illness or medical treatment.

    Who Are The Major Companies Operating In The Inactivated Vaccines Market?

    Major companies operating in the inactivated vaccines market are Pfizer Inc., Johnson & Johnson Services Inc., Sinopharm Group Co. Ltd., Merck & Co. Inc., Sanofi S.A., GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Astellas Pharma Inc., CSL Limited, Daiichi Sankyo Company Limited, Mitsubishi Tanabe Pharma Corporation, Novavax Inc., Zydus Lifesciences Ltd., Sinovac Biotech Ltd., Biological E Limited, Hualan Biological Engineering Inc., CanSino Biologics Inc., Shenzhen Kangtai Biological Products Co. Ltd., Serum Institute of India Pvt. Ltd., Beijing Tiatan Biological Products Co. Ltd., Valneva SE, Bavarian Nordic A/S., Beijing Minhai Biotechnology Co. Ltd., Bharat Biotech International Limited, Panacea Biotec Ltd., Sinergium Biotech SA, Bharat Immunologicals and Biologicals Corporation Limited, Haffkine Biopharmaceutical Corporation Limited, Incepta Vaccine Ltd., Changchun BCHT Biotechnology Co. Ltd., .

    Download The Full Report For Exclusive Market Findings:

    https://www.thebusinessresearchcompany.com/report/inactivated-vaccines-global-market-report

    What Regional Growth Trends Are Shaping The Inactivated Vaccines Market Outlook?

    North America was the largest region in the inactivated vaccines market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in inactivated vaccines market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

    Request A Customized Version Of The Inactivated Vaccines Market Report:

    https://www.thebusinessresearchcompany.com/customise?id=13018&type=smp

    Browse Through More Reports Similar to the Global Inactivated Vaccines Market 2025, By The Business Research Company

    Cancer Vaccine Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/cancer-vaccine-global-market-report

    Dtp Vaccine Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/dtp-vaccine-global-market-report

    Companion Animal Veterinary Vaccines Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/companion-animal-veterinary-vaccines-global-market-report

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Asia +44 7882 955267 & +91 8897263534

    Europe +44 7882 955267

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model